BioCentury
ARTICLE | Top Story

Achillion climbs on ACH-3102 data

February 10, 2015 1:50 AM UTC

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR12 after six weeks of treatment in a Phase II trial. The trial evaluated the combination in 12 treatment-naive patients, including seven with genotype 1a and five with 1b.

ACH-3012 is a pan-genotypic, second-generation HCV NS5A protein inhibitor. Sovaldi, a nucleotide analog HCV NS5B polymerase inhibitor, served as a proxy for ACH-3422, Achillion's small molecule nucleotide prodrug inhibitor of HCV NS5B polymerase. ...